Published in final edited form as:

Curr Top Microbiol Immunol. 2009 ; 336: 1–14. doi:10.1007/978-3-642-00549-7_1.

Chapter 1. Overview of Toll-like receptors (TLRs) in the CNS

Tammy Kielian

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE

Abstract

Mammalian Toll-like receptors (TLRs) were first identified in 1997 based on their homology with *Drosophila Toll*, which mediates innate immunity in the fly. Over the past 8 years, the number of manuscripts describing TLR expression and function in the central nervous system (CNS) has been increasing steadily and expanding beyond their traditional roles in infectious diseases to neurodegenerative disorders and injury. Interest in the field serves as the impetus for this volume in the *Current Topics in Microbiology and Immunology* series entitled “Toll-like receptors: Roles in Infection and Neuropathology”. The first five chapters highlight more traditional roles for TLRs in infectious diseases of the CNS. The second half of the volume discusses recently emerging roles for TLRs in non-infectious neurodegenerative diseases and the challenges faced in these models with identifying endogenous ligands. Several conceptual theories are introduced in various Chapters that deal with the dual nature of TLR engagement and whether these signals favor neuroprotective versus neurodegenerative outcomes.

1.1 Historical Background of TLRs

The *Toll* gene was first identified in *Drosophila* when a mutation introduced into the gene led to defects in dorsal-ventral patterning in the fly and an inability to completely coalesce the abdominal cavity (Lemaitre et al. 1996). Fortuitously, the discovery was also made that the *Toll* mutation resulted in enhanced susceptibility to fungal infections, providing the first clue that this receptor may participate in the fly innate immune response. Additional evidence came with the finding that a mutation in a distinct *Drosophila* receptor related to Toll, 18-wheeler, led to an increased prevalence of bacterial infections (Williams et al. 1997), reinforcing the pivotal roles that these receptors play in fly immunity. Subsequent sequencing of both the Toll and 18-wheeler genes revealed a significant degree of homology in the cytoplasmic tail with the cytoplasmic domain of the mammalian IL-1R (i.e. > 90%) (Anderson 2000). Based on this extraordinary degree of similarity, the search for mammalian homologues of Toll began and in 1997 the laboratory of the late Dr. Charles Janeway was the first to discover a Toll homolog in human monocytes, namely TLR4 (Medzhitov et al. 1997). Subsequent studies revealed that TLR4 was the receptor for LPS, a major immunostimulatory component of the outer cell wall of Gram-negative bacteria that had remained elusive for over 40 years. Later reports demonstrated that natural mutations in TLR4 were responsible for the LPS hyporesponsive nature of C3H/HeJ and B10 mice (Poltorak et al. 1998a; Hoshino et al. 1999; Qureshi et al. 1999). To date, a total of 13 TLRs have been identified in mice and 10 in humans, although ligands for a few of these receptors remain to be defined.

Innate immunity represents the first line of defense against invading microbes. In contrast, the adaptive immune response directed against microbial antigens takes several days to become established. Unlike adaptive immunity, where T and B cells can recognize an infinite repertoire of antigens due to random gene rearrangements of their receptors, cells of the innate immune system rely on a restricted set of germ-line encoded receptors that are directed against highly conserved motifs expressed by large classes of microorganisms. These conserved motifs have been coined pathogen-associated molecular patterns (PAMPs), and the receptors that recognize these structures are referred to pattern recognition receptors (PRRs) (Medzhitov and Janeway 2000; Qureshi and Medzhitov 2003; Kaisho and Akira 2004). In addition to traditional PAMPs, recent evidence has indicated that TLRs can recognize an array of endogenous molecules that are typically sequestered from the immune response, so called “danger signals” or danger-associated molecular patterns (DAMPs) (Matzinger 2002). In this issue of *Current Topics in Microbiology and Immunology*, chapters dedicated to both pathogen-derived and endogenous TLR ligands will be discussed. However, it is likely that during the course of CNS infectious diseases, self-antigens will be liberated as a consequence of cell death/necrosis and as such, TLR engagement may be elicited by a combination of PAMPs and DAMPs in this context.

In addition to driving innate immune responses to infectious pathogens, TLR-dependent signaling also initiates adaptive immunity (Hoebe et al. 2004; Pasare and Medzhitov 2004). This is particularly evident when considering that the engagement of TLRs by bacterial antigens is required to induce co-stimulatory molecule expression on antigen presenting cells (APC; i.e. dendritic cells and macrophages) for subsequent activation and expansion of antigen-specific T cells (Hertz et al. 2001; Boonstra et al. 2003; Pasare and Medzhitov 2003; Hoebe et al. 2004; Pasare and Medzhitov 2004). In addition, cytokines released by TLR-activated APCs, such as IL-12, play a pivotal role in regulating T cell development (Hoebe et al. 2004).

1.2 TLR Subtypes and Ligand Classification

Currently, there are 13 TLR family members that have been described in mice and 11 in humans, although some still remain relatively poorly characterized (i.e. TLR11, TLR12, TLR13). In terms of this introductory Chapter, a discussion of classical microbial TLR ligands will be presented followed by a description of endogenous TLR agonists that have been more recently described. This presentation order follows the organization of chapters in this Volume, namely the first portion of the book deals with the roles of TLRs in CNS infectious diseases, whereas the second portion addresses new emerging evidence that TLR signaling impacts the course of neurodegenerative disorders where pathogen etiologies are not apparent.

1.2.1 Extracellular TLRs and CNS Expression Patterns

There are several extracellular TLRs that recognize conserved structural motifs of large microbe populations. These motifs are typically less likely to undergo mutation since they are essential for pathogen survival. The most well-characterized and studied extracellular TLRs are TLR2 and TLR4, which recognize bacterial peptidoglycan (PGN)/lipoproteins and LPS, respectively. For the purposes of this introductory chapter, only these receptors will be

discussed; however, the reader is directed to several excellent review articles on the subject for more information (Akira et al. 2006; O'Neill and Bowie 2007).

TLR2 is capable of recognizing the widest array of PAMPs identified to date, including PGN, bacterial lipoproteins (i.e. tripalmitoyl-S-glycerol-cysteine; Pam3Cys), atypical LPS from *Prophyromonas gingivitis* and *Leptospira interrogans*, glycosylphosphatidylinositol lipid from *Trypanosoma cruzi*, and yeast zymosan (Qureshi and Medzhitov 2003; Takeda et al. 2003).

Several studies have demonstrated that microglia express TLR2 (Laflamme et al. 2001; Bsibsi 2002; Kielian et al. 2002; Rasley et al. 2002; Zekki et al. 2002; Laflamme et al. 2003; Olson and Miller 2004; Kielian et al. 2005) and receptor expression is elevated in response to a wide array of TLR2 agonists including PGN and Pam3Cys as well as alternative TLR ligands (i.e. LPS) (Laflamme et al. 2001; Rasley et al. 2002; Laflamme et al. 2003; Olson and Miller 2004). Another PRR that has been reported to cooperate with TLR2 is CD14, which is expressed on cells of the myeloid lineage including microglia and macrophages (Becher et al. 1996; Nadeau and Rivest 2000; Saito et al. 2000; Kielian et al. 2002; Kielian et al. 2005). CD14 is a glycosylphosphatidyl inositol (GPI)-anchored receptor and is involved in the recognition of Gram-positive PAMPs such as PGN and LTA through its ability to interact with TLR2/TLR1 and/or TLR2/TLR6 heterodimers (Cleveland et al. 1996; Gupta et al. 1996; Dziarski et al. 2000; Henneke et al. 2001; Schroder et al. 2003; Weber et al. 2003; Manukyan et al. 2005). More classically, CD14 is known for its ability to pair with TLR4 to transduce activation signals in response to LPS (Hazirot et al. 1988; Dobrovolskaia and Vogel 2002; Fitzgerald et al. 2004; Palsson-McDermott and O'Neill 2004).

Astrocytes also express TLR2, with augmented receptor levels observed upon exposure to various PAMPs (Bowman et al. 2003; Esen et al. 2004; Carpentier et al. 2005). Strong evidence demonstrating that astrocytes express TLR2 *in vivo* was shown by Mishra et al. using immunofluorescence staining. In this study, robust TLR2 immunoreactivity was detected in astrocytes in both the normal and infected CNS (Mishra et al. 2006). Further support for astrocytic TLR2 expression was provided by a recent report by Kigerl et al. that utilized laser capture microdissection for astrocyte enrichment from control and injured spinal cord tissues and demonstrated TLR2 expression associated with astrocytes, although maximal expression was detected in microglia (Kigerl et al. 2007). However, studies examining TLR2 in other systems have produced some conflicting results with regard to astrocytic expression (Bsibsi 2002; Rivest 2003; Farina et al. 2005; Owens 2005). It is likely that the context of PAMP exposure and/or strength of the activation signal received following astrocyte activation may dictate whether TLR2 expression is induced. This "Strength of Signal" concept has been proposed by Trevor Owens in Chapter 6 to address these discrepancies. Alternative explanations may include the species from which astrocytes were procured, route of PAMP administration in *in vivo* studies, and/or the length of time that astrocytes are co-cultured with microglia prior to purification in *in vitro* studies.

As mentioned earlier, TLR4 is responsible for recognizing the Gram-negative cell wall component LPS (Poltorak et al. 1998a; Poltorak et al. 1998b; Heine et al. 1999; Hoshino et al. 1999; Qureshi et al. 1999; Takeuchi et al. 1999; Hirschfeld et al. 2000; Lien et al. 2000;

Tapping et al. 2000). With respect to glia, it has long been acknowledged that LPS serves as a potent stimulus for microglial activation typified by the robust production of numerous proinflammatory mediators. Therefore, it was not unexpected when microglia were reported to express TLR4 (Laflamme and Rivest 2001; Bsibsi 2002; Lehnardt et al. 2002; Laflamme et al. 2003; Lehnardt et al. 2003; Rivest 2003; Olson and Miller 2004; Chakravarty and Herkenham 2005; Jung et al. 2005). As previously mentioned, CD14 interacts with TLR4 to induce maximal responses to LPS in macrophages and microglia (Dobrovolskaia and Vogel 2002; O'Neill 2004; Palsson-McDermott and O'Neill 2004; Esen and Kielian 2005).

In contrast to microglia, it appears more controversial as to whether astrocytes express TLR4. Several groups have been unable to demonstrate astrocytic TLR4 expression *in vitro* (Farina et al. 2005)(Kielian, unpublished observations) or *in vivo* (Laflamme and Rivest 2001; Lehnardt et al. 2002; Lehnardt et al. 2003); however, others have been able to detect low, constitutive expression of TLR4 in astrocytes that is increased upon cell activation (Bsibsi 2002; Bowman et al. 2003; Carpentier et al. 2005). It is important to acknowledge that great care must be taken when working with primary astrocytes to ensure that contamination with microglia is relatively low (Saura 2007). Since microglia express high levels of TLR4, a small level of residual microglia could introduce artifact signals that are not reflective of astrocytic receptor expression. This topic has also been discussed in Chapter 6 of this volume. Further studies using primary astrocyte cultures where microglia have been depleted by immunological means (i.e. magnetic bead purification or FACS using CD11b) will help to resolve this lingering issue.

1.2.2 Intracellular TLRs and CNS Expression Patterns

Not all TLRs are expressed at the plasma membrane; rather, several including TLR3, TLR7/8, and TLR9 are associated with endosomal membranes intracellularly. The intracellular expression patterns of these TLRs appears logical given the fact that their ligands represent nucleic acid motifs of pathogens that are typically not found extracellularly. Indeed, these nucleic acid motifs are typically encountered during intracellular replication and/or within intracellular compartments following phagocytosis. TLR3 recognizes dsRNA, which is an intermediate produced during viral replication in cells (Alexopoulou et al. 2001). Studies investigating the potential role of TLR3-mediated signaling commonly utilize the synthetic TLR3 agonist poly-inosine:cytosine (polyI:C); however, TLR3 expression does not appear to be regulated by poly(I:C) in microglia (Bsibsi 2002; Olson and Miller 2004), which differs from some of the other TLRs where receptor levels are augmented following exposure to their natural agonist(s) (Olson and Miller 2004; Kielian et al. 2005). Unlike the discrepancy in TLR4 expression, there is a consensus that astrocytes do express TLR3 (Bsibsi 2002; Carpentier et al. 2005; Farina et al. 2005; Scumpia et al. 2005; Farina et al. 2007). A central role for astrocytes in sensing viral infections in the CNS is supported by the finding that cells are responsive to the TLR3 agonist poly(I:C) as evident by the production of several proinflammatory mediators.

TLR7 and TLR8 are highly homologous TLRs and their ligands include single stranded RNA (ssRNA) as well as structurally similar synthetic chemicals including antiviral and anticancer compounds (Kaisho and Akira 2004). TLR7 and TLR8 expression has been

reported in microglia (Bsibsi 2002; Olson and Miller 2004), astrocytes (Carpentier et al. 2005), and more recently neurons (Ma et al. 2006; Ma et al. 2007), where TLR8 expression drives neuronal phenotypic changes and regulates apoptosis.

TLR9 mediates responses to bacterial DNA, viral DNA, and synthetic oligodeoxynucleotides (ODN), all of which contain unmethylated CpG motifs (Takeda et al. 2003). Both microglia (Takeshita et al. 2001; Dalpke et al. 2002; Iliev et al. 2004; Olson and Miller 2004; Zhang et al. 2005) and astrocytes (Bowman et al. 2003; Hosoi et al. 2004; Carpentier et al. 2005) express TLR9 and engagement of this PRR leads to a robust induction of pro-inflammatory mediators.

Following pathogen infection, it is likely that these intracellular TLRs serve to amplify the host immune response that was initially triggered by extracellular TLRs to ensure effective pathogen clearance. However, in the context of non-infectious neurodegeneration, the pathologic engagement of intracellular TLRs by endogenous ligands may contribute to exacerbated immune responses and enhance neuropathology. These issues are discussed in Chapters 6–10 of this *CMTI* volume.

Recently, several studies have described endogenous molecules that are capable of triggering TLR-dependent signaling cascades (Tsan and Gao 2004). One issue that has confounded progress in this area is the concern of reagent purity; in particular, earlier studies describing TLR-dependent signaling pathways for endogenous molecules were complicated by contaminating LPS (Tsan and Gao 2004). However, in spite of this issue, convincing evidence has emerged documenting the ability of several endogenous molecules to engage TLRs, with the majority stimulating either TLR2 or TLR4 (Tsan and Gao 2004; Kielian 2006). Despite the fact that several CNS models of CNS injury have been shown to be influenced by TLR2 and/or TLR4-dependent signaling, the identity of the ligand(s) that trigger these receptors remains elusive.

1.3 TLR Signaling Pathways

TLR engagement culminates in the induction of NF- κ B and MAPK signaling pathways, both of which regulate the expression of a wide array of genes involved in immune responses. Since the majority of TLRs utilize the central adaptor molecule MyD88 to transduce signaling cascades, this scheme will be discussed briefly with differences in TLR3-dependent signaling to follow (Akira 2006; O'Neill and Bowie 2007). TLR activation results in the recruitment of the adaptor protein MyD88 which is associated with the serine/threonine kinase interleukin-1 receptor-associated kinase (IRAK). Subsequently, IRAK interacts with TNF receptor-associated factor (TRAF) adaptor protein TRAF6, which provides a bridge to the protein kinase NF- κ B inducing kinase (NIK). Next, NIK phosphorylates IKK (I κ B kinase) leading to I κ B phosphorylation. I κ B phosphorylation targets the protein for ubiquitination and proteasome-mediated degradation, resulting in the release and nuclear translocation of NF- κ B, whereupon it can influence the expression of numerous immune response genes. However, recent evidence has demonstrated the existence of alternative adaptor molecules that transduce signals from TLRs via a MyD88-independent pathway (Akira and Takeda 2004). These adaptors include TRAM and TRIF

which are pivotal for the expression of IFN-inducible genes following TLR4 activation (Yamamoto et al. 2003; Akira and Takeda 2004; Yamamoto et al. 2004). These same adaptor molecules are required for TLR3-mediated signaling in response to dsRNA and are responsible for the induction of type I interferons (i.e. IFN- α and IFN- β) that are a hallmark host innate immune response to viral infection. Both TRIF and TRAM are also capable of transducing signals through TLR4 via a MyD88-dependent pathway to induce type I IFN production.

1.4 Highlights of Contributing Chapters and Emerging Concepts

The objective of this volume is to provide a current synopsis on the role of TLRs during both infectious and non-infectious diseases affecting the CNS. Traditionally, TLRs have been regarded as pathogen sensors and as such, the early TLR literature in the CNS was focused on this topic. However, recent studies utilizing various TLR-deficient mouse strains have revealed that TLRs can also impact the course of distinct neurodegenerative diseases/pathologies. Although the ligand(s) responsible for triggering TLR involvement in the absence of infectious insults have not yet been elucidated, it is apparent that these PRRs play a role, at some level, in influencing the subsequent host immune response to injury/trauma and the subsequent regenerative response. It is anticipated that this book will serve as a forum to bring to light the various outstanding questions that remain in the field as well as introduce new concepts regarding the roles of TLRs in CNS diseases and importantly, acknowledge the complexity of TLR signaling and the likelihood that TLRs act in concert with additional receptors to orchestrate the subsequent inflammatory profile.

The first four chapters of this book address the roles of TLRs in various models of CNS infectious disease including bacterial meningitis, brain abscess, and viral and parasitic infections that target the brain. Several interesting concepts emerge from these discussions that one should keep in mind that emphasize the relatedness of TLR involvement despite the distinct infectious etiologies and diverse TLR engagement employed. This suggests that infectious insults may elicit a “common initial pathway” for inflammation that can be further refined to accomplish the outcome required to neutralize the specific pathogen. This would translate to an early conserved innate immune response followed by a tailored pathogen-specific cascade. This concept remains to be supported or refuted, but nonetheless, comparisons between diverse infectious disease models should be made and the results utilized to make such determinations. This is one objective of assimilating these chapters in one volume.

Another commonality shared between the various infectious disease models presented in this book is the fact that the resultant immune response (mediated, in part, via TLRs) not only leads to pathogen destruction but also bystander damage to surrounding CNS parenchyma by necrotic/apoptotic cell death. Therefore, it is also possible that during CNS infections TLRs play two roles in ligand recognition: one is to facilitate the initial response to the enciting pathogen and upon tissue destruction, TLRs may also recognize newly liberated self-antigens as a result of necrotic/apoptotic death, a so-called “pathogen-necrosis-autoantigen triad” that is proposed in Chapter 3. This could conceivably account for the exaggerated inflammatory response that typically accompanies these CNS infectious

disorders. This concept remains to be tested; however, it remains an intriguing area for future investigation. It is clear from studies described in subsequent chapters of this book that agonist(s) liberated following CNS injury/insult are indeed capable of engaging TLRs to modulate the host response to damage. It remains to be seen whether a protective anti-pathogen response could be dissociated from a potential deleterious anti-self response following the liberation of endogenous TLR ligands to minimize damage to surrounding normal CNS tissue during these infectious insults.

When comparing the roles of TLRs in bacterial meningitis (Chapter 2) versus brain abscess (Chapter 3), although both infections occur in a distinct CNS compartment and involve different responding effector cells during the initial phase of disease, remarkably there are some commonalities observed. For example, both TLR2- and MyD88-dependent signals influence the pathogenesis of both infections. There is more consistency between the two models in terms of MyD88 where the loss of signaling leads to dramatic defects in host innate immunity and the failure to clear infection. In contrast, although TLR2-deficient mice do exhibit some deficits in bacterial clearance and depressed pro-inflammatory mediator production, these mice do not experience overt clinical decline as compared to MyD88-deficient animals in either the bacterial meningitis or brain abscess models. These findings implicate the involvement of additional PRRs that participate in bacterial recognition and amplification of immune networks. In addition, the cross-talk between TLRs and phagocytic PRRs must also be addressed since changes in cytokine expression patterns can influence phagocytic indices (Mukhopadhyay et al. 2004; Underhill and Gantner 2004). Future studies utilizing mice that are deficient for both a particular TLR and phagocytic PRR would be interesting to test the interplay between these molecules.

Another example of the intriguing complexity that could impact TLR signaling during CNS infectious is illustrated by helminth infections, which is the topic of Chapter 5 of this volume. Namely, many parasites that target the CNS harbor their own commensal bacteria. It is intriguing to speculate that parasite death results in a complex milieu of TLR ligands not only originating from the parasite itself but also its endogenous microflora.

One intriguing observation that has emerged from studies in various models of neurodegeneration/injury is the finding of microglia/macrophage heterogeneity that is dependent on the context of inflammation. This concept is illuminated in Chapter 7 with regard to the divergent ability of infiltrating macrophages following traumatic spinal cord injury to exhibit either neuro-destructive or neuro-protective properties. It has been proposed by the authors that TLR2 and TLR4 may favor inflammation during the acute stage of injury; however, these same TLRs may serve to promote repair processes/recovery during the later phases of disease (Chapter 7). Another explanation is provided in Chapter 6, where a “Strength of Signal” hypothesis is introduced. This concept states that neuroprotective versus detrimental effects of microglia in the CNS is dictated by the concentration of TLR ligand/agonist that these cells are exposed to *in vivo* (Chapter 6). It is important to acknowledge that both lines of thought are not mutually exclusive and raise important concepts that warrant further investigation in experimental systems.

Additional complexities regarding TLR signaling are raised in Chapter 8 in the context of Alzheimer's disease. In particular, it is evident that extensive receptor complexity exists involving TLRs and CD14 in the recognition of β -amyloid and dictating whether phagocytosis versus pro-inflammatory mediator production is induced. Likewise, Chapter 9 reveals divergent roles for MyD88-dependent versus -independent signaling in either exacerbating or attenuating disease severity in rodent models of multiple sclerosis (i.e. experimental autoimmune encephalomyelitis), respectively.

Chapter 10 highlights recent evidence implicating TLR signaling in mediating nerve degeneration/regeneration and neuropathic pain following nerve injury. In common with the other contributions covering topics of neurodegeneration/injury, it remains to be determined what factor(s) dictate whether TLR signaling is beneficial for reparative processes or rather induces pathology and chronic pain responses. Teasing apart these mechanisms may afford new therapeutic treatment modalities for the management of neuropathic pain, which represents a significant socioeconomic burden.

It is important to remind the reader that although it is tempting to assign the phenotypes obtained with MyD88-deficient mice to TLRs, this conclusion cannot be assumed. This is namely because MyD88 is utilized for signaling via the IL-1R and IL-18R as well as TLRs confounding the interpretations that can be made. This is all the more relevant since studies in models of CNS infectious diseases have demonstrated important roles for IL-1 and IL-18 in the host anti-bacterial immune response (Zwijnenburg et al. 2003a; Zwijnenburg et al. 2003b; Kielian et al. 2004). Future studies using mice that are deficient for two TLRs that are suspected to influence the course of disease are needed or alternatively, animals could be engineered that lack both the IL-1R and a particular TLR of interest.

Acknowledgments

Dr. Kielian's laboratory is supported by grants from the NIH National Institute of Neurological Disorders and Stroke (RO1s NS055385, NS40730, and NS053487).

List of Abbreviations

APC	Antigen presenting cell
CNS	Central nervous system
CTMI	Current Topics in Microbiology and Immunology
DAMP	Danger-associated molecular pattern
dsRNA	Double-stranded RNA
FACS	Fluorescent-activated cell sorting
IFN	Interferon
IκB	Inhibitory-kappa B
IKK	Inhibitory- κ B kinase
IL	Interleukin

IL-1R	Interleukin-1 receptor
IL-18R	Interleukin-18 receptor
IRAK	Interleukin-1 receptor-associated kinase
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
MAPK	Mitogen-activated protein kinase
MyD88	Myeloid differentiation primary-response protein 88
NF-κB	Nuclear factor-kappa B
NIK	NF- κ B-inducing kinase
ODN	Oligodeoxynucleotide
Pam3Cys	tripalmitoyl-S-glycerol-cysteine
PAMP	Pathogen-associated molecular pattern
PGN	Peptidoglycan
PolyI:C	Poly-inosine:cytosine
PRR	Pattern recognition receptor
ssRNA	Single-stranded RNA
TIRAP	Toll-interleukin 1 receptor (TIR) domain-containing adaptor protein
TLR	Toll-like receptor
TRAF	Tumor necrosis factor receptor-associated factor
TRIF	TIR-domain-containing adaptor inducing interferon- β

1.5 References

- Akira S. TLR signaling. *Curr Top Microbiol Immunol*. 2006; 311:1–16. [PubMed: 17048703]
- Akira S, Takeda K. Toll-like receptor signalling. *Nat Rev Immunol*. 2004; 4:499–511. [PubMed: 15229469]
- Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell*. 2006; 124:783–801. [PubMed: 16497588]
- Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature*. 2001; 413:732–738. [PubMed: 11607032]
- Anderson KV. Toll signaling pathways in the innate immune response. *Curr Opin Immunol*. 2000; 12:13–19. [PubMed: 10679407]
- Becher B, Fedorowicz V, Antel JP. Regulation of CD14 expression on human adult central nervous system-derived microglia. *PG - 375–81. J Neurosci Res*. 1996; 45
- Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu YJ, O'Garra A. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. *J Exp Med*. 2003; 197:101–109. [PubMed: 12515817]
- Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. *Glia*. 2003; 43:281–291. [PubMed: 12898707]

- Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. *J Neuropathol Exp Neurol*. 2002; 61(11):1013–1021. [PubMed: 12430718]
- Carpentier PA, Begolka WS, Olson JK, Elhofy A, Karpus WJ, Miller SD. Differential activation of astrocytes by innate and adaptive immune stimuli. *Glia*. 2005; 49:360–374. [PubMed: 15538753]
- Chakravarty S, Herkenham M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. *J Neurosci*. 2005; 25:1788–1796. [PubMed: 15716415]
- Cleveland MG, Gorham JD, Murphy TL, Tuomanen E, Murphy KM. Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. *Infect Immun*. 1996; 64:1906–1912. [PubMed: 8675286]
- Dalpke AH, Schafer MK, Frey M, Zimmermann S, Tebbe J, Weihe E, Heeg K. Immunostimulatory CpG-DNA activates murine microglia. *J Immunol*. 2002; 168:4854–4863. [PubMed: 11994434]
- Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. *Microbes Infect*. 2002; 4:903–914. [PubMed: 12106783]
- Dziarski R, Ulmer AJ, Gupta D. Interactions of CD14 with components of gram-positive bacteria. *Chem Immunol*. 2000; 74:83–107. [PubMed: 10608083]
- Esen N, Kielian T. Recognition of *Staphylococcus aureus*-derived peptidoglycan (PGN) but not intact bacteria is mediated by CD14 in microglia. *J Neuroimmunol*. 2005; 170:93–104. [PubMed: 16229899]
- Esen N, Tanga FY, DeLeo JA, Kielian T. Toll-like receptor 2 (TLR2) mediates astrocyte activation in response to the Gram-positive bacterium *Staphylococcus aureus*. *J Neurochem*. 2004; 88:746–758. [PubMed: 14720224]
- Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. *Trends Immunol*. 2007; 28:138–145. [PubMed: 17276138]
- Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E. Preferential expression and function of Toll-like receptor 3 in human astrocytes. *J Neuroimmunol*. 2005; 159:12–19. [PubMed: 15652398]
- Fitzgerald KA, Rowe DC, Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. *Microbes Infect*. 2004; 6:1361–1367. [PubMed: 15596121]
- Gupta D, Kirkland TN, Viriyakosol S, Dziarski R. CD14 is a cell-activating receptor for bacterial peptidoglycan. *J Biol Chem*. 1996; 271:23310–23316. [PubMed: 8798531]
- Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. *J Immunol*. 1988; 141:547–552. [PubMed: 3385210]
- Heine H, Kirschning CJ, Lien E, Monks BG, Rothe M, Golenbock DT. Cutting edge: cells that carry a null allele for toll-like receptor 2 are capable of responding to endotoxin. *J Immunol*. 1999; 162:6971–6975. [PubMed: 10358136]
- Henneke P, Takeuchi O, van Strijp JA, Guttormsen HK, Smith JA, Schromm AB, Espevik TA, Akira S, Nizet V, Kasper DL, Golenbock DT. Novel engagement of CD14 and multiple toll-like receptors by group B streptococci. *J Immunol*. 2001; 167:7069–7076. [PubMed: 11739528]
- Hertz CJ, Kiertscher SM, Godowski PJ, Bouis DA, Norgard MV, Roth MD, Modlin RL. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. *J Immunol*. 2001; 166:2444–2450. [PubMed: 11160304]
- Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. *J Immunol*. 2000; 165:618–622. [PubMed: 10878331]
- Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. *Nat Immunol*. 2004; 5:971–974. [PubMed: 15454919]
- Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. *J Immunol*. 1999; 162:3749–3752. [PubMed: 10201887]
- Hosoi T, Suzuki S, Nomura J, Ono A, Okuma Y, Akira S, Nomura Y. Bacterial DNA induced iNOS expression through MyD88-p38 MAP kinase in mouse primary cultured glial cells. *Brain Res Mol Brain Res*. 2004; 124:159–164. [PubMed: 15135224]

- Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). *FASEB J*. 2004; 18:412–414. [PubMed: 14688201]
- Jung DY, Lee H, Jung BY, Ock J, Lee MS, Lee WH, Suk K. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-beta as a decision maker. *J Immunol*. 2005; 174:6467–6476. [PubMed: 15879150]
- Kaisho T, Akira S. Pleiotropic function of Toll-like receptors. *Microbes Infect*. 2004; 6:1388–1394. [PubMed: 15596125]
- Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. *J Neurosci Res*. 2006; 83:711–730. [PubMed: 16541438]
- Kielian T, Bearden ED, Baldwin AC, Esen N. IL-1 and TNF-alpha play a pivotal role in the host immune response in a mouse model of *Staphylococcus aureus*-induced experimental brain abscess. *J Neuropathol Exp Neurol*. 2004; 63:381–396. [PubMed: 15099027]
- Kielian T, Esen N, Bearden ED. Toll-like receptor 2 (TLR2) is pivotal for recognition of *S. aureus* peptidoglycan but not intact bacteria by microglia. *Glia*. 2005; 49:567–576. [PubMed: 15593098]
- Kielian T, Mayes P, Kielian M. Characterization of microglial responses to *Staphylococcus aureus*: effects on cytokine, costimulatory molecule, and Toll-like receptor expression. *J Neuroimmunol*. 2002; 130:86–99. [PubMed: 12225891]
- Kigerl KA, Lai W, Rivest S, Hart RP, Satoskar AR, Popovich PG. Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. *J Neurochem*. 2007
- Laflamme N, Echchannaoui H, Landmann R, Rivest S. Cooperation between toll-like receptor 2 and 4 in the brain of mice challenged with cell wall components derived from gram-negative and gram-positive bacteria. *Eur J Immunol*. 2003; 33:1127–1138. [PubMed: 12672079]
- Laflamme N, Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. *FASEB J*. 2001; 15:155–163. [PubMed: 11149903]
- Laflamme N, Soucy G, Rivest S. Circulating cell wall components derived from gram-negative, not gram-positive, bacteria cause a profound induction of the gene-encoding Toll-like receptor 2 in the CNS. *J Neurochem*. 2001; 79:648–657. [PubMed: 11701768]
- Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, Rosenberg PA, Volpe JJ, Vartanian T. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. *J Neurosci*. 2002; 22:2478–2486. [PubMed: 11923412]
- Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. *Proc Natl Acad Sci U S A*. 2003; 100:8514–8519. [PubMed: 12824464]
- Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in *Drosophila* adults. *Cell*. 1996; 86:973–983. [PubMed: 8808632]
- Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. *J Clin Invest*. 2000; 105:497–504. [PubMed: 10683379]
- Ma Y, Haynes RL, Sidman RL, Vartanian T. TLR8: an innate immune receptor in brain, neurons and axons. *Cell Cycle*. 2007; 6:2859–2868. [PubMed: 18000403]
- Ma Y, Li J, Chiu I, Wang Y, Sloane JA, Lu J, Kosaras B, Sidman RL, Volpe JJ, Vartanian T. Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. *J Cell Biol*. 2006; 175:209–215. [PubMed: 17060494]
- Manukyan M, Triantafilou K, Triantafilou M, Mackie A, Nilsen N, Espevik T, Wiesmuller KH, Ulmer AJ, Heine H. Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1. *Eur J Immunol*. 2005; 35:911–921. [PubMed: 15714590]
- Matzinger P. The danger model: a renewed sense of self. *Science*. 2002; 296:301–305. [PubMed: 11951032]
- Medzhitov R, Janeway C Jr. Innate immunity. *N Engl J Med*. 2000; 343:338–344. [PubMed: 10922424]

- Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the *Drosophila* Toll protein signals activation of adaptive immunity. *Nature*. 1997; 388:394–397. [PubMed: 9237759]
- Mishra BB, Mishra PK, Teale JM. Expression and distribution of Toll-like receptors in the brain during murine neurocysticercosis. *J Neuroimmunol*. 2006; 181:46–56. [PubMed: 17011049]
- Mukhopadhyay S, Herre J, Brown GD, Gordon S. The potential for Toll-like receptors to collaborate with other innate immune receptors. *Immunology*. 2004; 112:521–530. [PubMed: 15270722]
- Nadeau S, Rivest S. Role of microglial-derived tumor necrosis factor in mediating CD14 transcription and nuclear factor kappa B activity in the brain during endotoxemia. *PG - J Neurosci*. 2000; 20
- Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. *J Immunol*. 2004; 173:3916–3924. [PubMed: 15356140]
- O'Neill LA. TLRs: Professor Mechnikov, sit on your hat. *Trends Immunol*. 2004; 25:687–693. [PubMed: 15530840]
- O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. *Nat Rev Immunol*. 2007; 7:353–364. [PubMed: 17457343]
- Owens T. Toll-like receptors on astrocytes: patterning for immunity. *J Neuroimmunol*. 2005; 159:1–2. [PubMed: 15652397]
- Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. *Immunology*. 2004; 113:153–162. [PubMed: 15379975]
- Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. *Science*. 2003; 299:1033–1036. [PubMed: 12532024]
- Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. *Microbes Infect*. 2004; 6:1382–1387. [PubMed: 15596124]
- Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in *Tlr4* gene. *Science*. 1998a; 282:2085–2088. [PubMed: 9851930]
- Poltorak A, Smirnova I, He X, Liu MY, Van Huffel C, McNally O, Birdwell D, Alejos E, Silva M, Du X, Thompson P, Chan EK, Ledesma J, Roe B, Clifton S, Vogel SN, Beutler B. Genetic and physical mapping of the *Lps* locus: identification of the toll-4 receptor as a candidate gene in the critical region. *Blood Cells Mol Dis*. 1998b; 24:340–355. [PubMed: 10087992]
- Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (*Tlr4*). *J Exp Med*. 1999; 189:615–625. [PubMed: 9989976]
- Qureshi ST, Medzhitov R. Toll-like receptors and their role in experimental models of microbial infection. *Genes Immun*. 2003; 4:87–94. [PubMed: 12618855]
- Rasley A, Anguita J, Marriott I. *Borrelia burgdorferi* induces inflammatory mediator production by murine microglia. *J Neuroimmunol*. 2002; 130:22–31. [PubMed: 12225885]
- Rivest S. Molecular insights on the cerebral innate immune system. *Brain Behav Immun*. 2003; 17:13–19. [PubMed: 12615045]
- Saito S, Matsuura M, Tominaga K, Kirikae T, Nakano M. Important role of membrane-associated CD14 in the induction of IFN-beta and subsequent nitric oxide production by murine macrophages in response to bacterial lipopolysaccharide. *Eur J Biochem*. 2000; 267:37–45. [PubMed: 10601848]
- Saura J. Microglial cells in astroglial cultures: a cautionary note. *J Neuroinflammation*. 2007; 4:26. [PubMed: 17937799]
- Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U, Gobel UB, Weber JR, Schumann RR. Lipoteichoic acid (LTA) of *Streptococcus pneumoniae* and *Staphylococcus aureus* activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. *J Biol Chem*. 2003; 278:15587–15594. [PubMed: 12594207]
- Scumpia PO, Kelly KM, Reeves WH, Stevens BR. Double-stranded RNA signals antiviral and inflammatory programs and dysfunctional glutamate transport in TLR3-expressing astrocytes. *Glia*. 2005

- Takeda K, Kaisho T, Akira S. Toll-like receptors. *Annu Rev Immunol.* 2003; 21:335–376. [PubMed: 12524386]
- Takeshita S, Takeshita F, Haddad DE, Janabi N, Klinman DM. Activation of microglia and astrocytes by CpG oligodeoxynucleotides. *Neuroreport.* 2001; 12:3029–3032. [PubMed: 11568631]
- Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. *Immunity.* 1999; 11:443–451. [PubMed: 10549626]
- Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. *J Immunol.* 2000; 165:5780–5787. [PubMed: 11067937]
- Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. *J Leukoc Biol.* 2004; 76:514–519. [PubMed: 15178705]
- Underhill DM, Gantner B. Integration of Toll-like receptor and phagocytic signaling for tailored immunity. *Microbes Infect.* 2004; 6:1368–1373. [PubMed: 15596122]
- Weber JR, Freyer D, Alexander C, Schroder NW, Reiss A, Kuster C, Pfeil D, Tuomanen EI, Schumann RR. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. *Immunity.* 2003; 19:269–279. [PubMed: 12932360]
- Williams MJ, Rodriguez A, Kimbrell DA, Eldon ED. The 18-wheeler mutation reveals complex antibacterial gene regulation in Drosophila host defense. *Embo J.* 1997; 16:6120–6130. [PubMed: 9321392]
- Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, Akira S. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. *Nat Immunol.* 2003; 4:1144–1150. [PubMed: 14556004]
- Yamamoto M, Takeda K, Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. *Mol Immunol.* 2004; 40:861–868. [PubMed: 14698224]
- Zekki H, Feinstein DL, Rivest S. The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. *Brain Pathol.* 2002; 12:308–319. [PubMed: 12146799]
- Zhang Z, Guo K, Schluesener HJ. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif. *J Neuroimmunol.* 2005; 161:68–77. [PubMed: 15748945]
- Zwijnenburg PJ, van der Poll T, Florquin S, Akira S, Takeda K, Roord JJ, van Furth AM. Interleukin-18 gene-deficient mice show enhanced defense and reduced inflammation during pneumococcal meningitis. *J Neuroimmunol.* 2003a; 138:31–37. [PubMed: 12742650]
- Zwijnenburg PJ, van der Poll T, Florquin S, Roord JJ, Van Furth AM. IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense against pneumococcal meningitis. *J Immunol.* 2003b; 170:4724–4730. [PubMed: 12707352]